BMC Complementary Medicine and Therapies (Feb 2022)

Screening the components of Saussurea involucrata for novel targets for the treatment of NSCLC using network pharmacology

  • Dongdong Zhang,
  • Tieying Zhang,
  • Yao Zhang,
  • Zhongqing Li,
  • He Li,
  • Yueyang Zhang,
  • Chenggong Liu,
  • Zichao Han,
  • Jin Li,
  • Jianbo Zhu

DOI
https://doi.org/10.1186/s12906-021-03501-0
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 19

Abstract

Read online

Abstract Background Saussurea involucrata (SAIN), also known as Snow lotus (SI), is mainly distributed in high-altitude areas such as Tibet and Xinjiang in China. To identify novel targets for the prevention or treatment of lung adenocarcinoma and lung squamous cell carcinoma (LUAD&LUSC), and to facilitate better alternative new drug discovery as well as clinical application services, the therapeutic effects of SAIN on LUAD&LUSC were evaluated by gene differential analysis of clinical samples, compound target molecular docking, and GROMACS molecular dynamics simulation. Results Through data screening, alignment, analysis, and validation it was confirmed that three of the major active ingredients in SAIN, namely quercetin (Q), luteolin (L), and kaempferol (K), mainly act on six protein targets, which mainly regulate signaling pathways in cancer, transcriptional misregulation in cancer, EGFR tyrosine kinase inhibitor resistance, adherens junction, IL-17 signaling pathway, melanoma, and non-small cell lung cancer. In addition, microRNAs in cancer exert preventive or therapeutic effects on LUAD&LUSC. Molecular dynamics (MD) simulations of Q, L, or K in complex with EGFR, MET, MMP1, or MMP3 revealed the presence of Q in a very stable tertiary structure in the human body. Conclusion There are three active compounds of Q, L, and K in SAIN, which play a role in the treatment and prevention of non-small cell lung cancer (NSCLC) by directly or indirectly regulating the expression of genes such as MMP1, MMP3, and EGFR.

Keywords